- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00000869
A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies
A Phase III Randomized, Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women
The purpose of this study is to see if giving the anti-HIV drug nevirapine (NVP) to HIV-positive pregnant women and their babies can help reduce the chance that a mother will give HIV to her baby during delivery. This study will also test the safety of the drug and see how well it is tolerated by the mother and her baby.
Previous studies suggest that NVP is a promising medication for blocking HIV transmission from HIV-positive mothers to their babies.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Nevirapine has several properties that make it an attractive candidate for antiretroviral therapy to interrupt HIV-1 transmission in the intrapartum and early postpartum period. The pharmacokinetic profile suggested that nevirapine would be rapidly absorbed and transferred to the infant in utero when given during labor and delivery. In addition, nevirapine has been shown to penetrate cell-free virions and inactivate virion-associated reverse transcriptase (RT) in situ. This property would be potentially useful in inactivating cell-free virions in the genital tract as well as in breast milk. These characteristics of nevirapine suggest that treatment of an HIV-infected pregnant woman in labor with an oral dose of nevirapine may provide a prophylactic level of nevirapine in the infant during the time of exposure to virus in the birth canal and/or maternal blood. In addition, nevirapine may inactivate the virion-associated RT present in cell-free virions in the genital tract or breast milk.
Women are randomized to receive either NVP or the corresponding placebo in active labor. Women are randomized at any time after their 32nd week gestation [AS PER AMENDMENT 1/13/98: 28th week gestation] [AS PER AMENDMENT 2/23/00: 20th week gestation]. The randomization is stratified using two factors: (1) use of [AS PER AMENDMENT 2/23/00: current or anticipated] antiretroviral therapy during the current pregnancy (no therapy at all; monotherapy for any duration; multi-agent therapy for any duration), and (2) CD4 cell count at the time of randomization (less than 200 cells; 200 - 399 cells; 400 cells or greater). Mothers are followed on study for 4 to 6 weeks postpartum. Mothers are also encouraged to follow the regimen of zidovudine (ZDV) outlined in the Office of Public Health and Science (PHS) treatment guidelines for both themselves and their infants. Infants are administered either NVP or placebo between 48 and 72 hours of life. The infant's study drug is the same as the mother's randomized treatment assignment. Infants are dosed with the study drug according to their randomization group regardless of whether the mother received the study drug. Infants are followed for 4 to 6 weeks, and are tested for HIV at 4 to 6 weeks, 3 months, and 6 months.
Tipo de estudio
Inscripción
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- Univ of Alabama at Birmingham - Pediatric
-
Mobile, Alabama, Estados Unidos, 36604
- Univ of South Alabama
-
-
California
-
La Jolla, California, Estados Unidos, 920930672
- UCSD Med Ctr / Pediatrics / Clinical Sciences
-
Long Beach, California, Estados Unidos, 90801
- Long Beach Memorial (Pediatric)
-
Los Angeles, California, Estados Unidos, 90033
- Los Angeles County - USC Med Ctr
-
Los Angeles, California, Estados Unidos, 905022004
- Harbor - UCLA Med Ctr / UCLA School of Medicine
-
Los Angeles, California, Estados Unidos, 900951752
- UCLA Med Ctr / Pediatric
-
San Francisco, California, Estados Unidos, 94110
- San Francisco Gen Hosp
-
San Francisco, California, Estados Unidos, 941430105
- UCSF / Moffitt Hosp - Pediatric
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 802181088
- Children's Hosp of Denver
-
-
Connecticut
-
Farmington, Connecticut, Estados Unidos, 06032
- Univ of Connecticut / Farmington
-
Farmington, Connecticut, Estados Unidos, 060303805
- Connecticut Children's Med Ctr
-
-
District of Columbia
-
Washington, District of Columbia, Estados Unidos, 200102931
- Washington Hosp Ctr
-
Washington, District of Columbia, Estados Unidos, 20060
- Howard Univ Hosp
-
-
Florida
-
Fort Lauderdale, Florida, Estados Unidos, 33311
- North Broward Hosp District
-
Gainesville, Florida, Estados Unidos, 32610
- Univ of Florida Gainesville
-
Jacksonville, Florida, Estados Unidos, 32209
- Univ of Florida Health Science Ctr / Pediatrics
-
Miami, Florida, Estados Unidos, 33161
- Univ of Miami (Pediatric)
-
Miami, Florida, Estados Unidos, 33136
- Univ of Miami / Jackson Memorial Hosp
-
-
Georgia
-
Augusta, Georgia, Estados Unidos, 30912
- Med College of Georgia
-
Columbus, Georgia, Estados Unidos, 31901
- The Med Ctr Inc
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Cook County Hosp
-
Chicago, Illinois, Estados Unidos, 606143394
- Chicago Children's Memorial Hosp
-
Chicago, Illinois, Estados Unidos, 606371470
- Univ of Chicago Children's Hosp
-
Chicago, Illinois, Estados Unidos, 60612
- Univ of Illinois College of Medicine / Pediatrics
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 701122699
- Tulane Univ / Charity Hosp of New Orleans
-
New Orleans, Louisiana, Estados Unidos, 701122699
- Tulane Univ Hosp of New Orleans
-
New Orleans, Louisiana, Estados Unidos, 70112
- Univ Hosp
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21201
- Univ of Maryland at Baltimore / Univ Med Ctr
-
Baltimore, Maryland, Estados Unidos, 212874933
- Johns Hopkins Hosp - Pediatric
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Brigham and Women's Hosp
-
Boston, Massachusetts, Estados Unidos, 021155724
- Children's Hosp of Boston
-
Boston, Massachusetts, Estados Unidos, 02118
- Boston City Hosp / Pediatrics
-
Springfield, Massachusetts, Estados Unidos, 01199
- Baystate Med Ctr of Springfield
-
Worcester, Massachusetts, Estados Unidos, 016550001
- Univ of Massachusetts Med School
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Children's Hosp of Michigan
-
-
Mississippi
-
Jackson, Mississippi, Estados Unidos, 39213
- Univ of Mississippi Med Ctr
-
-
New Jersey
-
Camden, New Jersey, Estados Unidos, 08103
- Cooper Hosp - Univ Med Ctr / UMDNJ - New Jersey Med Schl
-
New Brunswick, New Jersey, Estados Unidos, 089030019
- UMDNJ - Robert Wood Johnson Med School / Pediatrics
-
New Brunswick, New Jersey, Estados Unidos, 08903
- St Peter's Med Ctr
-
Newark, New Jersey, Estados Unidos, 071032714
- Univ of Medicine & Dentistry of New Jersey / Univ Hosp
-
Newark, New Jersey, Estados Unidos, 07103
- Saint Joseph's Hosp and Med Ctr/UMDNJ - New Jersey Med Schl
-
-
New York
-
Albany, New York, Estados Unidos, 12208
- Children's Hosp at Albany Med Ctr
-
Bronx, New York, Estados Unidos, 10461
- Bronx Municipal Hosp Ctr/Jacobi Med Ctr
-
Bronx, New York, Estados Unidos, 10457
- Bronx Lebanon Hosp Ctr
-
Great Neck, New York, Estados Unidos, 11021
- North Shore Univ Hosp
-
New York, New York, Estados Unidos, 10016
- Bellevue Hosp / New York Univ Med Ctr
-
New York, New York, Estados Unidos, 10029
- Metropolitan Hosp Ctr
-
New York, New York, Estados Unidos, 10032
- Columbia Presbyterian Med Ctr
-
Rochester, New York, Estados Unidos, 146420001
- Univ of Rochester Med Ctr
-
Syracuse, New York, Estados Unidos, 13210
- SUNY Health Sciences Ctr at Syracuse / Pediatrics
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 277103499
- Duke Univ Med Ctr
-
Durham, North Carolina, Estados Unidos, 27710
- Univ of North Carolina at Chapel Hill / Duke Univ Med Ctr
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 191044318
- Children's Hosp of Philadelphia
-
Philadelphia, Pennsylvania, Estados Unidos, 191341095
- Saint Christopher's Hosp for Children
-
Philadelphia, Pennsylvania, Estados Unidos, 191341095
- Temple Univ School of Medicine
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Hosp of the Univ of Pennsylvania
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 294253312
- Med Univ of South Carolina
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 381052794
- Saint Jude Children's Research Hosp of Memphis
-
Memphis, Tennessee, Estados Unidos, 38103
- Regional Med Ctr at Memphis
-
Memphis, Tennessee, Estados Unidos, 381052794
- Methodist Hosp Central
-
Nashville, Tennessee, Estados Unidos, 372322581
- Vanderbilt Univ Med Ctr
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75235
- Children's Med Ctr of Dallas
-
Houston, Texas, Estados Unidos, 77030
- Texas Children's Hosp / Baylor Univ
-
-
Virginia
-
Norfolk, Virginia, Estados Unidos, 23507
- Children's Hosp of the King's Daughters
-
Norfolk, Virginia, Estados Unidos, 23507
- Senetara Norfolk Gen Hosp
-
Richmond, Virginia, Estados Unidos, 23219
- Med College of Virginia
-
-
Washington
-
Seattle, Washington, Estados Unidos, 981050371
- Children's Hospital & Medical Center / Seattle ACTU
-
Tacoma, Washington, Estados Unidos, 98405
- Tacoma Gen Hosp
-
-
-
-
-
Bayamon, Puerto Rico, 00956
- Ramon Ruiz Arnau Univ Hosp / Pediatrics
-
San Juan, Puerto Rico, 009367344
- San Juan City Hosp
-
San Juan, Puerto Rico, 009365067
- Univ of Puerto Rico / Univ Children's Hosp AIDS
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria
Women may be eligible for this study if they:
- Are HIV-positive.
- Are at least 20 weeks pregnant. (This study has been changed. Women no longer have to be 28 weeks pregnant.)
- Have consent from the child's father (if available).
- Are at least 13 years old (consent of parent or guardian required if under 18).
Exclusion Criteria
Women will not be eligible for this study if they:
- Have ever taken NNRTIs (nonnucleoside reverse transcriptase inhibitors).
- Are enrolled in another pregnancy treatment study.
- Are allergic to benzodiazepines.
- Have liver disease.
- Plan to breast-feed.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Enmascaramiento: Doble
Colaboradores e Investigadores
Investigadores
- Silla de estudio: Alejandro Dorenbaum
- Silla de estudio: John Sullivan
Publicaciones y enlaces útiles
Publicaciones Generales
- Cunningham CK, Balasubramanian R, Delke I, Maupin R, Mofenson L, Dorenbaum A, Sullivan JL, Gonzalez-Garcia A, Thorpe E, Rathore M, Gelber RD. The impact of race/ethnicity on mother-to-child HIV transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316. J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):800-7. doi: 10.1097/00126334-200407010-00006.
- Watts DH, Balasubramanian R, Maupin RT Jr, Delke I, Dorenbaum A, Fiore S, Newell ML, Delfraissy JF, Gelber RD, Mofenson LM, Culnane M, Cunningham CK; PACTG 316 Study Team. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol. 2004 Feb;190(2):506-16. doi: 10.1016/j.ajog.2003.07.018.
- Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, Dorenbaum A, Delfraissy JF, Bazin B, Mofenson L, Sullivan JL. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis. 2002 Jul 15;186(2):181-8. doi: 10.1086/341300. Epub 2002 Jun 26.
- Cunningham CK, Britto P, Gelber R, Dorenbaum A, Mofenson L, Culnane M, Sullivan JL. Genotypic resistance analysis in women participating in PACTG 316 with HIV-1 RNA >400 copies/ml. 8th Conf Retro and Opportun Infect. 2001 Feb 4-8 (abstract no 712)
- Mirochnick M, Dorenbaum A, Cunningham-Schrader B, Cunningham C, Gelber R, Mofenson L, Sullivan J. Cord blood protease inhibitor (PI) concentrations in infants born to mothers receiving PIs. 8th Conf Retro and Opportun Infect. 2001 Feb 4-8 (abstract no 710)
- Dorenbaum A. Report of results of PACTG 316: an international phase III trial of standard antiretroviral (ARV) prophylaxis plus nevirapine (NVP) for prevention of perinatal HIV transmission. 8th Conf Retro and Opportun Infect. 2001 Feb 4-8 (abstract no LB7)
- Mirochnick M, Dorenbaum A, Blanchard S, Cunningham CK, Gelber RD, Mofenson L, Culnane M, Sullivan JL. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Syndr. 2003 Jun 1;33(2):153-6. doi: 10.1097/00126334-200306010-00006.
- Newell ML, Huang S, Fiore S, Thorne C, Mandelbrot L, Sullivan JL, Maupin R, Delke I, Watts DH, Gelber RD, Cunningham CK; PACTG 316 Study Team. Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA. BMC Infect Dis. 2007 Jun 20;7:60. doi: 10.1186/1471-2334-7-60.
Fechas de registro del estudio
Fechas importantes del estudio
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Enfermedades del sistema inmunológico
- Infecciones por VIH
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Agentes Antivirales
- Inhibidores de la transcriptasa inversa
- Inhibidores de la síntesis de ácidos nucleicos
- Inhibidores de enzimas
- Agentes Anti-VIH
- Agentes antirretrovirales
- Inductores de enzimas de citocromo P-450
- Inductores de citocromo P-450 CYP3A
- Nevirapina
Otros números de identificación del estudio
- ACTG 316
- 11290 (Identificador de registro: DAIDS ES Registry Number)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Infecciones por VIH
-
Icahn School of Medicine at Mount SinaiIRRASReclutamientoHemorragia Intraventricular (HIV)Estados Unidos
-
Yale UniversityTerminadoPrecocidad | Recién nacidos de muy bajo peso al nacer | Hemorragia Intraventricular (HIV) | Sangrado en el cerebroEstados Unidos
-
China Medical University HospitalDesconocidoDisplasia broncopulmonar | Bebés extremadamente prematuros | TLP grave que las terapias convencionales han fallado | Sin anomalías congénitas graves | no Hiv Severa Ni FPV QuísticaTaiwán